版本:
中国

BRIEF-Astrazeneca presents Tagrisso trial data

June 6 Astrazeneca Plc

* Astrazeneca presents Tagrisso (osimertinib) data in patients with egfr t790m-mutation positive lung cancer and central nervous system metastases

* Tagrisso extended length of time patients with CNS metastases live without disease worsening/death to 11.7 months in AURA3 trial​

* E‍evidence of activity in patients with EGFR mutation-positive NSCLC and leptomeningeal metastases from bloom trial​

* Three patients had AE leading to death, however no deaths were considered possibly causally-related to osimertinib by investigator​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐